Company intelligence / Profile preview

BlueWillow Biologics

Ann Arbor, Michigan, United Statesbluewillow.com ↗

Ownership: Private
Development stage: Phase 1

Overview

BlueWillow has completed Phase 1 trials for their intranasal anthrax vaccine (BW-1010) with positive interim results showing safety, tolerability, and induction of systemic and mucosal immunity. Their H5N1 clinical trial has been completed with publication anticipated soon. The company's vaccines aim to elicit three-pronged mucosal, cellular, and systemic immune responses.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Intranasal vaccinesnanoemulsion-based vaccines
Industry: Biotech

Drug pipeline

17 assets

NB-001

16 more assets in the full pipeline.

Request access →

Partnerships

Porton Biopharma Limited (UK)National Institute of Allergy and Infectious Diseases (NIAID)

Beyond the preview

Go deeper on BlueWillow Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlueWillow Biologics.

Explore the full profile